Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGAV | P06756 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 3/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649344 | 0.92 | ITGB3 (0.43) | ITGB3ITGAVFFAR1GAAMAPT | |
| SCHEMBL14380634 | 0.92 | FFAR1 (0.51) | ITGB3ITGAVFFAR1GAAMAPT | |
| SCHEMBL14380635 | 0.92 | FFAR1 (0.51) | ITGB3ITGAVFFAR1GAAMAPT | |
| SCHEMBL14380639 | 0.87 | ITGB3 (0.40) | ITGB3ITGAVFFAR1L3MBTL1MAP4K4 | |
| SCHEMBL20141587 | 0.83 | KMT2A (0.40) | ITGB3ITGAVFFAR1GAAMAPT | |
| SCHEMBL20141591 | 0.83 | KMT2A (0.40) | ITGB3ITGAVFFAR1GAAMAPT | |
| SCHEMBL5648774 | 0.81 | ITGB3 (0.39) | ITGB3ITGAVFFAR1GAAMAPT | |
| SCHEMBL6221566 | 0.78 | ITGB3 (0.50) | ITGB3ITGAVFFAR1GAAMAPT | |
| SCHEMBL23722442 | 0.78 | KCNK3 (0.37) | ITGB3ITGAVFFAR1POLBCTSA | |
| SCHEMBL19987502 | 0.75 | TUBB4A (0.38) | ITGB3ITGAVFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1603906-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ALPHA V BETA 3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078109-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | AVPR1A, AVPR1B, ADRB3 | ITGB3 94/4885ITGAV 484/4885FFAR1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.